(Q36772871)

16 August 2017

title

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection (English)

1 reference

16 August 2017

1 reference

Locke JE

1

1 reference

16 August 2017

Zachary AA

2

1 reference

16 August 2017

Haas M

3

1 reference

16 August 2017

Melancon JK

4

1 reference

16 August 2017

Warren DS

5

1 reference

16 August 2017

Simpkins CE

6

1 reference

16 August 2017

Segev DL

7

1 reference

16 August 2017

Montgomery RA

8

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

American Journal of Transplantation

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

842-846

1 reference

Humoral theory of transplantation: mechanism, prevention, and treatment

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Current approaches to treatment of antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Overcoming a positive crossmatch in living-donor kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01709.X

10.1111/J.1600-6143.2006.01709.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference